Aspen close to new deal to produce vaccines in SA

accreditation
Aspen’s flagship manufacturing site in Gqebhera, Eastern Cape.
Aspen’s flagship manufacturing site in Gqebhera, Eastern Cape.
Photo: Aspen

Aspen said on Monday that it's in "advanced discussions" for a licensing agreement to allow it to produce and sell a Covid-19 vaccine in Africa.

The company, which is the biggest medicine producer on the continent, previous said it was in talks with Johnson & Johnson about a licence that would mean that it could make its own-branded Covid-19 vaccine.

Currently, Aspen has an agreement with Johnson & Johnson to package and fill vials of its vaccine at a plant in Gqeberha. 

A licence would enable Aspen to decide on the recipient of the doses it produces, Aspen CEO Stephen Saad told Bloomberg recently.

"The successful conclusion of this licensing agreement may have a material effect on the price of Aspen's securities and, accordingly, shareholders are advised to exercise caution when dealing in the company's securities," the company said in a statement. 


        

    
We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For 14 free days, you can have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed. 
Subscribe to News24
Rand - Dollar
15.85
+0.1%
Rand - Pound
19.76
+0.1%
Rand - Euro
16.73
+0.3%
Rand - Aus dollar
11.18
+0.0%
Rand - Yen
0.12
+0.2%
Gold
1,843.78
+0.1%
Silver
21.93
+0.1%
Palladium
2,016.50
+0.4%
Platinum
966.00
-0.1%
Brent Crude
112.04
+2.6%
Top 40
61,690
-0.1%
All Share
68,301
+0.1%
Resource 10
72,931
+2.2%
Industrial 25
74,321
-2.0%
Financial 15
15,851
+0.8%
All JSE data delayed by at least 15 minutes Iress logo
Company Snapshot